Genotoxicity and carcinogenicity studies of benzodiazepines

Pharmacological Research

Volumn 56, Issue 6, 2007, Pages 443-458

  Brambilla, Giovanni ^a   Carrozzino, Roberto ^b   Martelli, Antonietta ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b Drug Dependence Service   (Italy)

Author keywords

Benzodiazepines and benzodiazepine analogues; Carcinogenicity; Genotoxicity

Indexed keywords

ALPRAZOLAM; BENZODIAZEPINE DERIVATIVE; BROMAZEPAM; BROTIZOLAM; CAMAZEPAM; CHLORDIAZEPOXIDE; CLOBAZAM; CLONAZEPAM; CLORAZEPATE; CLOTIAZEPAM; DELORAZEPAM; DIAZEPAM; DOXEFAZEPAM; ESTAZOLAM; ETHYL LOFLAZEPATE; FLUNITRAZEPAM; FLURAZEPAM; FLUTAZOLAM; HALAZEPAM; LOPRAZOLAM; LORAZEPAM; LORMETAZEPAM; MEDAZEPAM; MIDAZOLAM; NITRAZEPAM; NORDAZEPAM; OXAZEPAM; OXAZOLAM; PHENAZEPAM; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CARCINOGENICITY; DRUG RESEARCH; GENE MUTATION; GENOTOXICITY; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; REVIEW; TOXICITY TESTING;

ANIMALS; BENZODIAZEPINES; CARCINOGENICITY TESTS; EPIDEMIOLOGIC STUDIES; HUMANS; HYPNOTICS AND SEDATIVES; MUTAGENICITY TESTS; NEOPLASMS;

EID: 36249013225     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2007.08.006     Document Type: Review

References (73)

1. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guideline for Industry. S2A. Specific Aspects of Regulatory Genotoxicity Tests for Pharmaceuticals; April 1996.
2. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for Industry. S2B Genotoxicity: A standard battery for genotoxicity testing of pharmaceuticals; July 1997.
3. Müller L., Kikuchi Y., Probst G., Schechtman L., Shimada H., Sofuni T., et al. ICH-harmonized guidance on genotoxicity testing of pharmaceuticals; evolution, reasoning and impact. Mutat Res 436 (1999) 195-225
4. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidelines for Industry. S1A. The need for long-term rodent carcinogenicity studies of pharmaceuticals; March 1996.
5. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for Industry. S1B. Testing for carcinogenicity of pharmaceuticals; July 1997.
6. Martindale. The complete drug reference. 34th ed. London: Pharmaceutical Press; 2005.
7. Physicians' Desk Reference. 59th ed. Motvale, NJ, USA: Thomson PDR; 2005.
8. International Agency for Research on Cancer. IARC monographs on the evaluation of carcinogenic risks to human, vol. 1-88. Lyon, France: IARC; 1972-2006.
9. Snyder R.D., and Green J.W. A review of the genotoxicity of marketed pharmaceuticals. Mutat Res 488 (2001) 151-169
10. U.S. Department of Health and Human Sciences. Registry of toxic effects of chemical substances, 1985-1986 ed. Washington; 1988.
11. Center for Drug Evaluation and Research, www.fda.gov/cder.
12. Carlo P., Finollo R., Ledda A., and Brambilla G. Absence of liver DNA fragmentation in rats treated with high oral doses of 32 benzodiazepine drugs. Fundam Appl Toxicol 12 (1989) 34-41
13. Lafi A., Parry E.M., and Parry J.M. The effects of benzodiazepines upon the fidelity of mitotic cell division in cultured Chinese hamster cells. Mutat Res 189 (1987) 319-332
14. Degraeve N., Chollet C., Moutschen J., Moutschen-Dahmen M., and Gilet-Delhalle J. Investigation on the potential mutagenic activity of benzodiazepines in mice. Mutat Res 147 (1985) 290
15. Hewett C., Ellenberger J., Köllmer H., Kreuzer H., Niggeschulze A., and Stötzer H. Safety assessment of brotizolam. Arzneim -Forsch 36 (1986) 592-600
16. Kier L.E., Brusick D.J., Auletta A.E., von Halle E.S., Brown M.M., Simmon V.F., et al. The Salmonella typhimurium/mammalian microsomal assay. A report of the U.S. Environmental Protection Agency Gene-Tox Program. Mutat Res 168 (1986) 69-240
17. Giri A.K., and Banerjee S. Genetic toxicology of four commonly used benzodiazepines: a review. Mutat Res 340 (1996) 93-108
18. Susheela M., and Rao M.S. Mutagenic potential of chlordiazepoxide hydrochloride in Drosophila melanogaster. Indian J Med Res 76 (1982) 348-351
19. Ishidate Jr. M., Harnois M.C., and Sofumi T. A comparative analysis of data on the clastogenicity of 951 chemical substances tested in mammalian cell cultures. Mutat Res 195 (1988) 151-213
20. Zimmermann F.K., von Borstel R.C., von Halle E.S., Parry J.M., Siebert D., Zetterberg G., et al. Testing of chemicals for genetic activity with Saccharomyces cerevisiae. A report of the U.S. Environmental Protection Agency Gene-Tox Program. Mutat Res 133 (1984) 199-244
21. Robbiano L., Carlo P., Finollo R., and Brambilla G. DNA damage induced in rats by oral administration of chlordiazepoxide plus sodium nitrite or of N-nitrosochlordiazepoxide. Toxicol Appl Pharmacol 102 (1990) 186-190
22. Susheela M., and Rao M.S. Genotoxicity of chlordiazepoxide hydrochloride on the bone marrow cells of Swiss mice. Toxicol Lett 18 (1983) 45-48
23. Kar R.N., and Das R.K. Citogenetic effect of chlordiazepoxide on the bone marrow cells of Swiss mice in vivo. Cytobios 36 (1983) 73-82
24. Kar R.N., and Das R.K. Induction of sperm head abnormalities in mice by three tranquilizer. Cytobios 36 (1983) 45-51
25. Yamakage K., Katoh M., Sakamoto K., Sasaki K., Hashimoto K., Ishihara N., et al. Mutagenicity tests of clobazam. Iyakuhin Kenkyu 25 (1994) 874-885
26. Barzaghi F., Fournex R., and Mantegazza P. Pharmacological and toxicological properties of clobazam (1-phenyl-5-methyl-8-chloro-1,2,4,5-tetrahydro-2,4-diketo-3H-1,5-benzodiazepine), a new psychotherapeutic agent. Arneimittelforsch 23 (1973) 683-686
27. Miyawaki I., Moriyasu M., Funabashi H., Yasuba M., and Matsuoka N. Mechanism of clobazam-induced thyroidal oncogenesis in male rats. Toxicol Lett 145 (2003) 291-301
28. Legator M.S., Bueding E., Batzinger R., Connor T.H., Eisenstadt E., Farrow M.G., et al. An evaluation of the host-mediated assay and body fluid analysis. A report of the U.S. Environmental Protection Agency Gene-Tox Program. Mutat Res 98 (1982) 319-374
29. Diwan B.A., Lubet R.A., Nims R.W., Klaunig J.E., Weghorst C.M., Henneman J.R., et al. Lack of promoting effect of clonazepam on the development of N-nitrosodiethylamine-initiated hepatocellular tumors in mice is correlated with its inability to inhibit cell-to-cell communication in mouse hepatocytes. Carcinogenesis 10 (1989) 1719-1724
30. Blum J.E., Haefely W., Jalfre M., Pole P., and Schärer K. Pharmakologie und Toxikologie des Antiepilecticum Clonazepam Arzneim-Fosh 23 (1973) 377-400
31. Mazue G., Remandet B., Gouy D., Berthe J., Roncucci R., and Williams G.M. Limited in vivo bioassay on some benzodiazepines: lack of experimental initiating or promoting effect of the benzodiazepine tranquillizers diazepam, clorazepate, oxazepam and lorazepam. Arch Int Pharmacodyn Ther 257 (1982) 59-65
32. Balbi A., Muscettola G., Staiano N., Martire G., and De Lorenzo F. Psychotropic drugs: evaluation of mutagenic effect. Pharmacol Res Commun 12 (1980) 423-431
33. International Agency for Research on Cancer. IARC monographs on the evaluation of the carcinogenic risk of chemicals to humans, some pharmaceutical drugs, vol. 66. Lyon, France: IARC; 1996.
34. Ibrulj S., and Nefic H. Diazepam-induced chromosome aberrations in human lymphocytes in vitro. Med Arh 53 (1999) 3-5
35. Neda K., Yamamoto K., Sato H., Sawai M., and Ishimura K. In vivo cytogenetic studies of 10-chloro-11b-(2-fluorophenyl)-7-(2-hydroxyethyl)-2,3,5, 11b-tetrahydrooxazolo-(3,2-d) (1,4) benzodiazepine-6(7H)-one (MS-4101) on rat bone marrow cells. Nippon Yakurigaku Zasshi 73 (1977) 651-656
36. Karahalil B., Yagar S., Bahadir G., Durak P., and Sardas S. Diazepam and propofol used as anesthetics during open-heart surgery do not cause chromosomal aberrations in peripheral blood lymphocytes. Mutat Res 581 (2005) 181-186
37. Diwan B.A., Rice J.M., and Ward J.M. Tumor-promoting activity of benzodiazepines tranquilizers, diazepam and oxazepam, in mouse liver. Carcinogenesis 7 (1986) 789-794
38. Borelli G., Bertoli D., and Chieco P. Carcinogenicity study of doxefazepam administered in the diet to Sprague-Dawley rats. Fundam Appl Toxicol 15 (1990) 82-92
39. Kimura E.T., Fort F.L., Buratto B., Tekeli S., Kesterson J.W., Heyman I.A., et al. Carcinogenic evaluation of estazolam via diet in CD strain Sprague-Dawley rats and B6C3F1 mice for 2 years. Fundam Appl Toxicol 4 (1984) 827-842
40. Staiano N., Belisario M.A.B., Della Morte R., Farina C., Rimondelli P., and Muscettola G. Mutagenic effects of flunitrazepam. Boll Soc It Biol Sper 60 (1984) 2247-2253
41. United States National Toxicology Program, testing-status. http://ntp-server.niehs.nih.gov.
42. Owen G., Hatfield G.K., Pollock J.J., Steinberg A.J., Tucker W.E., and Agersborg Jr. H.P. Toxicity studies of Lorazepam, a new benzodiazepine, in animals. Arzneim -Forsch 21 (1971) 1065-1073
43. Stoyanov I., Nikolov I., Chernozemskii I., and Stoichev I. Assessment for mutagenicity of 10 pharmaceutical products following Ames, micronucleus, and sperm morphology testing. Toxic Assess 2 (1987) 207-215
44. http://toxnet.nlm.nih.gov
45. Wakisaka Y., and Nishimoto Y. Mutagenicity study of a new sleep inducer, a 1H-1,2,4-triazolylbenzophenone derivative (450191-S), and its metabolite in bacteria. Iyakuhin Kenkyu 18 (1987) 12-20
46. Scott B.R., Dorn G.L., Käfer E., and Stafford R. Aspergillus nidulans: systems and results of tests for induction of mitotic segregation and mutation. II. Haploid assay systems and overall response of all systems. A report of the U.S. Gene-Tox Program. Mutat Res 98 (1982) 49-94
47. Kersten B., Kasper P., Brendler-Schwaab S.Y., and Muller L. Use of the photo-micronucleus assay in Chinese hamster V79 cells to study photochemical genotoxicity. Mutat Res 519 (2002) 49-66
48. Deutsch W.A., Kukreja A., Shane B., and Hegde V. Phenobarbital, oxazepam and Wyeth 14. 643 cause DNA damage as measures by the Comet assay. Mutagenesis 16 (2001) 439-442
49. Ibrulj S., and Duricic E. Genotoxicity of oxazepam - the micronucleus cytochalasin - B test. Med Arh 56 (2002) 61-64
50. Devereux T.R., White C.M., Sills R.C., Bucher J.R., Maronpot R.R., and Anderson M.W. Low frequency of H-ras mutations in hepatocellular adenomas and carcinomas and in hepatoblastomas from B6C3F1 mice exposed to oxazepam in the diet. Carcinogenesis 15 (1994) 1083-1087
51. Shane B.S., de Boer J.G., Glickman B.W., and Cunningham M.L. Oxazepam is mutagenic in vivo in Big Blue transgenic mice. Carcinogenesis 20 (1999) 1315-1321
52. Singh V.K., Ganesh L., Cunningham M.L., and Shane B.S. Comparison of the mutant frequencies and mutation spectra of three non-genotoxic carcinogens, oxazepam, phenobarbital, and Wyeth 14,643, at the lambda cII locus in Big Blue transgenic mice. Biochem Pharmacol 62 (2001) 685-692
53. Préat V., De Gerlache J., Laus M., and Roberfroid M. Promoting effect of oxazepam in rat hepatocarcinogenesis. Carcinogenesis 8 (1987) 97-100
54. Bucker J.R., Shackelford C.C., Haseman J.K., Johnson J.D., Kurtz P.J., and Persing R.L. Carcinogenicity studies of oxazepam in mice. Fundam Appl Toxicol 23 (1994) 280-297
55. United States National Toxicology Program. Toxicology and carcinogenesis studies of Oxazepam (CAS No. 604-75-1) in Swiss-Webster and B6C3F1 mice (feed studies). 1993 [NTP TR No. 443].
56. United States National Toxicology Program. Toxicology and carcinogenesis studies of oxazepam (CAS No. 604-75-1) in F344/N rats (feed studies). 1998 [NTP TR No. 468,1-189].
57. Bucker J.R., Haseman J.K., Herbert R.A., and Ryan M.J. Toxicity and carcinogenicity studies of oxazepam in the Fischer 344 rat. Toxicol Sci 42 (1998) 1-12
58. Seredenin S.B., Avrutskii G.Y.A., Fatkhulin I.A., Durnev A.D., Fot'yanov M.I., and Shevchenko N.M. Study of chromosome aberrations in the lymphocytes of patients treated with phenazepam and sydnocarb. Khim-Farm Zh 14 (1980) 14-18
59. Black H.E., Szot R.J., Arthaud L.E., Massa T., Mylecraine L., Klein M., et al. Preclinical safety evaluation of the benzodiazepine quazepam. Arzneim -Forsch 37 (1987) 906-913
60. Fitzgerald J.E., de la Iglesia F.A., and McGuire E.J. Carcinogenicity studies in rodents and ripazepam, a minor tranquilizing agent. Fundam Appl Toxicol 4 (1984) 178-190
61. Robison R.L., van Ryzin R.J., Stoll R.E., Jensen R.D., and Bagdon R.E. Chronic toxicity/carcinogenesis study of temazepam in mice and rats. Fundam Appl Toxicol 4 (1984) 394-405
62. Chlopkiewicz B., Ejchart A., and Anuszewska E. Tofisopam-evaluation of mutagenic and genotoxic properties. Acta Pol Pharm 58 (2001) 31-34
63. Scirus, http://www.scirus.com.
64. Coogan P.F., Rosenberg L., Palmer J.R., Strom B.L., Stolley P.D., Zauber A.G., et al. Risk of ovarian cancer according to use of antidepressant, phenothiazines, and benzodiazepines (United States). Cancer Causes Control 11 (2000) 839-845
65. Tennant R.W., Margolin B.H., Shelby M.D., Zeiger E., Haseman J.K., Spalding J., et al. Prediction of chemical carcinogenicity in rodents from in vitro genetic toxicity assays. Sciences 236 (1987) 933-941
66. Zeiger E., Haseman J.K., Shelby M.D., Margolin B.H., and Tennant R.W. Evaluation of four in vitro genetic toxicity tests for predicting rodent carcinogenicity: confirmation of earlier results with 41 additional chemicals. Environ Mol Mutagen 16 Suppl. 18 (1990) 1-14
67. Kirkland D., Aardema M., Henderson L., and Müller L. Evaluation of the ability of a battery of three in vitro genotoxicity tests to discriminate rodent carcinogens and non-carcinogens I. Sensitivity, specificity and relative predictivity. Mutat Res 584 (2005) 1-256
68. Kirkland D.J., Hayashi M., Jacobson-Kram D., Kasper P., MacGregor J.T., Müller L., et al. Summary of major conclusions from the 4th IWGT, San Francisco, 9-10 September 2005. Mutat Res 627 (2007) 5-9
69. Thybaud V., Aardema M., Clements J., Dearfield K., Galloway S., Hayashi M., et al. Strategy for genotoxicity testing: hazard identification and risk assessment in relation to in vitro testing. Mutat Res 627 (2007) 41-58
70. Tweats D.J., Blakey D., Heflich R.H., Jacobs A., Jacobsen S.D., Morita T., et al. Report of the IWGT working group on strategies and interpretation of regulatory in vivo tests. I. Increases in micronucleated bone marrow cells in rodents that do not indicate genotoxic hazards. Mutat Res 627 (2007) 78-91
71. International Agency for Research on Cancer. IARC Monographs on the evaluation of carcinogenic risks to humans. Suppl. 7, Overal evaluation of carcinogenicity: An updating of IARC monographs, vols. 1-42. Lyon, France: IARC; 1987.
72. Brambilla G., and Martelli A. Genotoxic and carcinogenic risk to humans of drug-nitrite interaction products. Mutat Res 635 (2007) 17-52
73. Brambilla G., Robbiano L., Martelli A., Cajelli E., Allavena A., and Mazzei M. Genotoxicity of N-nitrosochlordiazepoxide in cultured mammalian cells. Toxicol Appl Pharmacol 97 (1989) 480-488